Pacira Biosciences Inc expected to post earnings of 88 cents a share - Earnings Preview

Pacira Biosciences

27/02/2024 13:59

* Pacira Biosciences Inc  PCRX.OQ   PCRX.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
29 for the period ending December 31 2023
    * The Tampa Florida-based  company is expected to report a
5.6% increase in revenue to $181.662 million from $171.96
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Pacira Biosciences Inc
is for
earnings of 88 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pacira
Biosciences Inc is $45.00​, above​ its last closing price
of $29.74. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.77        0.78       0.72      Missed  -8.2
 Jun. 30 2023  0.77        0.76       0.78      Beat    2.9
 Mar. 31 2023  0.62        0.62       0.53      Missed  -14.1​
 Dec. 31 2022  0.82        0.83       0.80      Missed  -3.6
 ​​Sep.        0.71        0.76       0.64      Missed  -16.2
 30 2022                                                
 Jun. 30 2022  0.81        0.85       0.51      Missed  -40.1​
 Mar. 31 2022  0.80        0.83       0.64      Missed  -23.1
 Dec. 31 2021  0.82        0.90       0.97      Beat    7.4
 This summary was machine generated February 27 at 13:58 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)